[HTML] amegroups.org

[HTML][HTML] Efficacy, safety and prognostic factors analysis of first-line icotinib treatment in advanced non-small cell lung cancer patients with mutated EGFR

A Huang, Q Shen, X Yu, H Wang, C Shi… - Translational Cancer …, 2018 - tcr.amegroups.org
Background: This study aimed to evaluate the efficacy, safety and prognostic factors of
icotinib as first-line treatment in advanced non-small cell lung cancer (NSCLC) patients with …
被引用次数：4 相关文章
[PDF] amegroups.cn

[PDF][PDF] Efficacy, safety and prognostic factors analysis of first-line icotinib treatment in advanced non-small cell lung cancer patients with mutated EGFR

A Huang, Q Shen, X Yu, H Wang, C Shi… - Translational Cancer …, 2018 - cdn.amegroups.cn
Background: This study aimed to evaluate the efficacy, safety and prognostic factors of
icotinib as first-line treatment in advanced non-small cell lung cancer (NSCLC) patients with …

Efficacy, safety and prognostic factors analysis of first-line icotinib treatment in advanced non-small cell lung cancer patients with mutated EGFR

A Huang, Q Shen, X Yu, H Wang, C Shi… - Translational Cancer …, 2018 - tcr.amegroups.org
Background: This study aimed to evaluate the efficacy, safety and prognostic factors of
icotinib as first-line treatment in advanced non-small cell lung cancer (NSCLC) patients with …

[引用][C] Efficacy, safety and prognostic factors analysis of first-line icotinib treatment in advanced non-small cell lung cancer patients with mutated EGFR

A Huang, Q Shen, X Yu, H Wang, C Shi… - Translational Cancer …, 2018 - cir.nii.ac.jp
Efficacy, safety and prognostic factors analysis of first-line icotinib treatment in advanced non-small
cell lung cancer patients with mutated EGFR | CiNii Research CiNii 国立情報学研究所 学術 …